Direkt zum Inhalt
Merck
  • Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.

Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.

Bioorganic & medicinal chemistry letters (2011-08-20)
Edward E Knaus, Alessio Innocenti, Andrea Scozzafava, Claudiu T Supuran
ZUSAMMENFASSUNG

A series of compounds incorporating regioisomeric phenylethynylbenzenesulfonamide moieties has been investigated for the inhibition of four human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, hCA I, II, IX and XII. Inhibition between the low nanomolar to the milliomolar range has been observed against them, with several low nanomolar and tumor-CA selective inhibitors detected. The position of the sulfamoyl group with respect to the alkyne functionality, and the nature of the moieties substituting the second aromatic ring were the principal structural features influencing CA inhibition. The para-sulfamoyl-substituted derivatives were effective inhibitors of CA IX and XII, the meta-substituted regioisomers of CA I, IX and XII, whereas the ortho-substituted sulfonamides were weak inhibitors of CA I, II and IX, but inhibited significantly CA XII.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Sulfanilamid, ≥98%
Sigma-Aldrich
Sulfanilamid, puriss. p.a., ≥98% (calc. to the dried substance)
Supelco
Sulfanilamid, VETRANAL®, analytical standard